logo-loader
viewAIM ImmunoTech Inc.

Hemispherx reports positive survival data linked to stage 4 ovarian cancer using Ampligen as a combination therapy

Based on the Phase 1 study results, the company said that a new Phase 2 recurrent ovarian cancer clinical study has already begun at the University of Pittsburgh Medical Center

Hemispherx Biopharma Inc -
Hemispherx Biopharma CEO Thomas K Equels said the positive results in the Phase 1/2 study, are “extremely encouraging”

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) stock flew in premarket trade Thursday after it issued a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy with Intron A and Celecoxib for treating recurrent ovarian cancer.

In a statement, the company said the research team, led by Dr Robert Edwards, Anda Vlad and Brian Orr, found that Ampligen was “well tolerated” as a combination therapy.

Investors cheered the news, sending Hemispherx Biopharma stock up 30.4% to $2.70 before the opening bell.

READ: Hemispherx Biopharma issues updates for ongoing immunotherapy trials of its drug Ampligen

In the report, Dr Orr concluded that the “drugs can be given in this combination with no major toxicities.”

“The Phase 1 study, in addition to generating excellent safety data, has also produced positive survival data with regard to the stage 4 ovarian cancer patients participating in the recently completed recurrent ovarian cancer Phase 1 Study,” said Dr Edwards added.

Based on the Phase 1 study results, the company said that a new Phase 2 recurrent ovarian cancer clinical study has already begun at the University of Pittsburgh Medical Center treating stage 4 patients with Ampligen, cisplatin and pembrolizumab.

The 45-patient, Phase 2 trial in combination with pembrolizumab is designed to test the combinational synergy with checkpoint blockade therapy when Ampligen is administered by injection in the peritoneal cavity where the tumor is located.

Hemispherx Biopharma CEO Thomas K Equels said the positive results linked to safety and survival using Ampligen, as seen in the first stage 4 patients treated in the Phase 1/2 study, are “extremely encouraging.”

“The results are consistent with foundational research Hemispherx obtained in animals, as well as in clinical trials in humans with melanoma and renal cell carcinoma where Hemispherx chief medical officer Dr David Strayer was the principal investigator,” Equels added.

He noted that Dr Strayer’s investigations supported Ampligen’s ability to alter what’s known as the microenvironment of a tumor, essentially making it more susceptible to other cancer treatments.

Additionally, Ampligen is being used in a Phase 2a trial for colorectal cancer that has metastasized to the liver, and an open label study for metastatic triple negative breast cancer.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: AIM ImmunoTech Inc.

Price: 0.504 USD

NYSE:AIM
Market: NYSE
Market Cap: $2.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read